UBS lowered the firm’s price target on Bio-Rad (BIO) to $335 from $350 and keeps a Buy rating on the shares. While there were some bright spots, margins were “messy,” and the process chrom headwind was bigger than expected, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: